Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults

This study has been completed.
Information provided by:
Hoffmann-La Roche Identifier:
First received: November 2, 1999
Last updated: November 14, 2005
Last verified: November 2005
The purpose of this study is to see if it is safe and effective to give T-20, a new type of anti-HIV drug, with a combination of other anti-HIV drugs. The other anti-HIV drugs used are abacavir (ABC), amprenavir (APV), ritonavir (RTV), and efavirenz (EFV). Three different doses of T-20 are tested.

Condition Intervention Phase
HIV Infections
Drug: Enfuvirtide
Drug: Ritonavir
Drug: Abacavir sulfate
Drug: Amprenavir
Drug: Efavirenz
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Controlled Phase 2 Trial Assessing Three Doses of T-20 in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz in HIV-1 Infected Adults

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Estimated Enrollment: 68
Study Start Date: May 1999
Detailed Description:
Patients are assigned to one of four groups. Three dose groups receive a background antiretroviral regimen (ABC, APV, RTV, and EFV) and T-20, which is given at one of three doses on a twice-daily regimen. The fourth group (control) receives the background antiretroviral regimen alone. For each treatment group, 17 patients are enrolled. Treatment is administered for 16 weeks, followed by a 32-week treatment extension, and a 2-week follow-up period. The following are assessed throughout the trial: safety parameters (as measured by hematology, clinical chemistry, urinalysis, and treatment-emergent adverse events); virologic and immunologic activity; phenotypic and genotypic resistance; T-20 plasma levels; and pharmacokinetics of T-20 and oral antiretrovirals. The total study duration is 1 year.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

Patients may be eligible for this study if they:

  • Are HIV-positive.
  • Have an HIV level (viral load) between 400 and 100,000 copies/ml at the screening visit.
  • Have taken at least 1 PI (protease inhibitor) for at least 16 weeks, and have had no interruptions in their most recent PI-containing anti-HIV drug regimen.
  • Are at least 18 years old.
  • Agree to abstinence or use of 2 effective methods of birth control, including a barrier method, during the study.

Exclusion Criteria

Patients will not be eligible for this study if they:

  • Have ever taken an NNRTI (nonnucleoside reverse transcriptase inhibitor).
  • Have an opportunistic (HIV-related) infection.
  • Have had an unexplained fever of at least 38.5 C for 7 days in a row within 30 days prior to screening.
  • Have had diarrhea lasting at least 15 days within 30 days prior to screening.
  • Have ever taken abacavir, amprenavir, or efavirenz (ABC, APV, or EFV).
  • Have certain genetic characteristics (drug resistance mutations) that could change the way a drug acts in the body.
  • Are allergic to any of the study medications.
  • Have a tumor other than certain skin or cervical cancers.
  • Are on chemotherapy that cannot be discontinued during the study.
  • Are taking an investigational drug within 30 days prior to screening.
  • Have ever received an HIV vaccine.
  • Are taking certain medications.
  • Abuse drugs or alcohol.
  • Have hemophilia or another blood clotting disorder.
  • Have had an organ transplant.
  • Are pregnant or breast-feeding.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00002239

United States, California
Pacific Oaks Research
Beverly Hills, California, United States, 90211
UCLA Care Ctr
Los Angeles, California, United States, 90095
ViRx Inc
Palm Springs, California, United States, 92262
Donald Northfelt
Palm Springs, California, United States, 92270
San Diego, California, United States, 92103
ViRx Inc
San Francisco, California, United States, 94109
Quest Clinical Research
San Francisco, California, United States, 94115
United States, District of Columbia
Dupont Circle Physicians Group
Washington, District of Columbia, United States, 200091104
United States, Florida
IDC Research Initiative
Altamonte Springs, Florida, United States, 32701
Gary Richmond MD
Fort Lauderdale, Florida, United States, 33316
United States, Georgia
AIDS Research Consortium of Atlanta
Atlanta, Georgia, United States, 30308
United States, Maryland
Johns Hopkins Hosp
Baltimore, Maryland, United States, 21287
United States, Missouri
Washington Univ School of Medicine
St. Louis, Missouri, United States, 63110
United States, New York
New York Univ Med Ctr
New York, New York, United States, 10016
United States, North Carolina
Trimeris Inc
Durham, North Carolina, United States, 27707
United States, Oklahoma
Associates of Med and Mental Health
Tulsa, Oklahoma, United States, 74114
United States, Pennsylvania
Pennsylvania Oncology and Hematology Associates
Philadelphia, Pennsylvania, United States, 19106
Philadelphia FIGHT
Philadelphia, Pennsylvania, United States, 19107
Univ of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15261
United States, Texas
Central Texas Clinical Research
Austin, Texas, United States, 78705
Sponsors and Collaborators
Hoffmann-La Roche
  More Information Identifier: NCT00002239     History of Changes
Other Study ID Numbers: T20-206
Study First Received: November 2, 1999
Last Updated: November 14, 2005

Keywords provided by Hoffmann-La Roche:
Dose-Response Relationship, Drug
Drug Therapy, Combination
VX 478
Anti-HIV Agents

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Cytochrome P-450 CYP2C9 Inhibitors
Cytochrome P-450 CYP2C19 Inhibitors
Cytochrome P-450 CYP2B6 Inducers processed this record on April 21, 2017